Deutsch English Français

Contact

EP2470901

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2470901

EP2470901 - USE OF IMMUNOREGULATORY NK CELL POPULATIONS FOR PREDICTING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS [Right-click to bookmark this link]
Status	The application has been withdrawn Status updated on 05.10.2012 Database last updated on 23.09.2024
Most recent event Tooltip	05.10.2012	Withdrawal of application	published on 07.11.2012 [2012/45]
Applicant(s)	For all designated states Abbott Biotherapeutics Corp. 1500 Seaport Boulevard Redwood City, CA 94063 / US
	[N/P]
Former [2012/27]	For all designated states Abbott Biotherapeutics Corp. 1500 Seaport Boulevard Redwood City CA 94063 / US
Inventor(s)	01 / SHERIDAN III, James Peter 1058 Tulane Drive Mountain View California 94040 / US
	[2012/27]
Representative(s)	Roques, Sarah Elizabeth, et al J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	[2012/27]
Application number, filing date	10773516.9	29.10.2010
	WO2010US54699
Priority number, date	US20090256761P	30.10.2009 Original published format: US 256761 P
	[2012/27]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2011053777
	Date:	05.05.2011
	Language:	EN
	[2011/18]
	Type:	A1 Application with search report
	No.:	EP2470901
	Date:	04.07.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 05.05.2011 takes the place of the publication of the European patent application.
	[2012/27]
Search report(s)	International search report - published on:	EP	05.05.2011
Classification	IPC:	G01N33/50, G01N33/564	[2012/27]
	CPC:	G01N33/6869 (EP,US); A61K39/395 (EP,US); A61K45/06 (EP,US); A61P25/00 (EP); G01N33/56972 (EP,US); G01N2333/7155 (EP,US); (+) G01N2800/285 (EP,US); G01N2800/52 (EP,US) (-)
	C-Set:	A61K39/395, A61K2300/00 (EP,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/27]
Extension states	BA	28.03.2012
	ME	28.03.2012
Title	German:	VERWENDUNG VON IMMUNREGULATORISCHEN NK-ZELLPOPULATIONEN ZUR VORHERSAGE DER WIRKSAMKEIT VON ANTI-IL-2R-ANTIKÖRPERN BEI PATIENTEN MIT MULTIPLER SKLEROSE	[2012/27]
	English:	USE OF IMMUNOREGULATORY NK CELL POPULATIONS FOR PREDICTING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS	[2012/27]
	French:	UTILISATION DE POPULATIONS DE CELLULES NK IMMUNORÉGULATRICES POUR PRÉDIRE L'EFFICACITÉ D'ANTICORPS ANTI-IL-2R DANS DES PATIENTS ATTEINTS DE SCLÉROSE EN PLAQUES	[2012/27]
Entry into regional phase	28.03.2012	National basic fee paid
	28.03.2012	Designation fee(s) paid
	28.03.2012	Examination fee paid
Examination procedure	28.03.2012	Examination requested [2012/27]
	01.10.2012	Application withdrawn by applicant [2012/45]
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XA] - BIELEKOVA BIBIANA ET AL, "Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, (20090401), vol. 66, no. 4, ISSN 0003-9942, pages 483 - 489, XP009129266 [X] 34,36-51 * p. 484/485, "Study Treatment" * [A] 1-33,35
		[XA] - LINKER RALF A ET AL, "Innovative monoclonal antibody therapies in multiple sclerosis.", THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, (200807), vol. 1, no. 1, ISSN 1756-2856, pages 33 - 42, XP002617116 [X] 34,36-51 * abstract * * "Daclizumab"; page 39 - page 40 * [A] 1-33,35 DOI: http://dx.doi.org/10.1177/1756285608093945
		[A] - SHERIDAN J ET AL, "Expansion of CD56bright NK cells correlates with therapeutic response to daclizumab in multiple sclerosis", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200909), Database accession no. PREV200900588640, XP002617117 [A] 1-51 * abstract *
		[A] - JP.Sheridan et al, "Expansion of CD65bright NK Cells Correlates with Therapeutic Response to Daclizumab in Multiple sclerosis", (20090909), URL: http://facetbiotech.com/images/uploads/pdfs/ECTRIMS_P430_DAC_poster_2009.pdf, (20010114) [A] 1-51 * the whole document *
		[A] - BIELEKOVA BIBIANA ET AL, "Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 103, no. 15, doi:10.1073/PNAS.0601335103, ISSN 0027-8424, (20060411), pages 5941 - 5946, (20060403), XP002605860 [A] 1-51 * the whole document * DOI: http://dx.doi.org/10.1073/PNAS.0601335103
		[AP] - WYNN DANIEL ET AL, "Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 9, no. 4, doi:10.1016/S1474-4422(10)70033-8, ISSN 1474-4422, (20100401), pages 381 - 390, (20100215), XP002605861 [AP] 1-51 * the whole document * DOI: http://dx.doi.org/10.1016/S1474-4422(10)70033-8
	by applicant	US5530101
		US5585089
		US5693761
		US5693762
		US6180370
		EP0239400
		WO9109967
		US5225539
		EP0592106
		EP0519596
		US5565332
		US5011684
		US5152980
		US5336489
		US5510105
		US5571507
		US5587162
		US5607675
		US5674494
		US5916559
		US2003138417
		US2006029599
		- MONTALBAN, X. ET AL., MULTIPLE SCLEROSIS, (200710), vol. 13, no. 2, pages S18 - S18
		- KAUFINAN, M.D. ET AL., NEUROLOGY, (20080311), vol. 70, no. 11, pages A220 - A220
		- WAHL ET AL., J. NUCL. MED., (1983), vol. 24, page 316
		- GLENN E. MORRIS,, Methods in Molecular Biology, (1996), vol. 66
		- HAMMERLING ET AL., Monoclonal Antibodies and T-Cell Hybridomas, ELSEVIER, (1981), page 563 681
		- PADLAN, MOL. IMMUNOL., (1991), vol. 28, page 489 498
		- STUDNICKA ET AL., PROT. ENG., (1994), vol. 7, page 805 814
		- ROGUSKA ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, page 969 973
		- BAAN ET AL., TRANSPLANT. PROC., (2001), vol. 33, pages 224 - 2246
		- BIELEKOVA, B. ET AL., PROC NATL ACAD SCI USA, (2006), vol. 103, pages 5941 - 5946
		- SHERIDAN, JP ET AL., NEUROLOGY, (2009), vol. 72, no. 11, pages A35 - A35
		- PERINI ET AL., J NEUROLOGY, (2004), vol. 251, pages 305 - 309
		- SORENSEN ET AL., LANCET, (2003), vol. 362, pages 184 - 191
		- PACHNER, NEUROLOGY, (2003), vol. 61, no. 5, pages S2 - S5
		- FARRELL ET AL., MULTIPLE SCLEROSIS, (2008), vol. 14, pages 212 - 218
		- SORENSEN ET AL., LANCET, (2003), vol. 362, pages 1184 - 1191
		- LEE ET AL., BRAIN, (1999), vol. 122, pages 1211 - 2
		- MALUCCHI ET AL., NEUROLOGY, (2004), vol. 62, pages 2031 - 2037
		- QUEEN ET AL., PROC. NATL. ACAD. SCI., (1989), vol. 86, pages 1029 - 1033
		- LEHKY ET AL., ANN. NEURO., (1998), vol. 44, pages 942 - 947
		- NUSSENBLATT ET AL., PROC. NATL. ACAD. SCI., (1999), vol. 96, pages 7462 - 7466
		- KAUFMAN, M.D., NEUROLOGY, (20080311), vol. 70, no. 11, pages A220 - A220

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p